Yamunanagar faces pollution crisis: 8 formaldehyde plants under scrutiny of pollution board
As the 15-day deadline given to eight formaldehyde manufacturing units in Yamunanagar by the Haryana State Pollution Control Board (HSPCB), it raises serious questions about the next course of action by the district administration.
These units were and are still operating without mandatory environmental clearances and in violation of the Water Act and Air Act and the order of the Supreme Court.
As per Sudhir Mohan, Executive Regional Officer (ERO) of the Yamunanagar of HSPCB, plant owners were issued notices on June 21 under the Water (Prevention and Control of Pollution) Act, 1974, and the Air (Prevention and Control of Pollution) Act, 1981. They were asked to show cause why prosecution, closure orders, and environmental compensation should not be initiated against them.
These eight units are established in different parts of Yamunanagar district including Yamunanagar, Jathlana, Jagadhri, Chhachhrauli, Radaur and others.
ERO Sudhir said these units have submitted their replies after the notices, which are currently under scrutiny. He said after the scrutiny the report will be sent to the HSPCB headquarters for further action. The HSPCB in its notices warned that if they fail to meet the required environmental standards and secure Environmental Clearance (EC), closure notices will be issued.
by Taboola
by Taboola
Sponsored Links
Sponsored Links
Promoted Links
Promoted Links
You May Like
Don't Pay Full Price for 2025's Top Games!
G2A.COM
Shop Now
Undo
The fate of these formaldehyde units could have a ripple effect on the local plywood industry. Formaldehyde is an essential chemical used in the production of resin, which binds plywood layers together. Without it, the industry cannot function. This chemical's pollution has cancer causing substances, said Yamunanagar deputy civil surgeon.
According to JK Bihani, District President of the Plywood Factory Association, 'Formaldehyde is the backbone of the plywood industry.
If these plants shut down, over 160 active plywood units could follow, especially when 190 have already closed due to recession.'
Formaldehyde is classified as a hazardous chemical known to cause health issues like cancer, respiratory irritation, allergies, and skin problems. Its industrial use, especially in adhesive resins, requires strict regulation and environmental approval, which many of the plants had reportedly bypassed for years.
Officials say a final decision on enforcement actions, including possible shutdowns, will be made after examining the responses submitted by the plant operators. As scrutiny continues, the region's critical plywood manufacturing economy hangs in the balance.
Yamunanagar deputy civil surgeon Dr Divya Mangla said, 'When formaldehyde is dissolved in water, it is very hazardous for the human body. It can lead to irritation, respiratory problems and even can lead to cancer. It is very important to stop pollution from this chemical and protect air, water and the environment for better human health.'
With the deadline now passed and the stakes high, the coming days will be crucial for Yamunanagar's environment and economy alike.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
27 minutes ago
- Indian Express
Abortions based on ‘presumed' mental health injury: HC seeks Centre opinion on plea challenging law
The Punjab and Haryana High Court has sought the Union government's reply to a Public Interest Litigation (PIL) filed by a 57-year-old Hisar resident challenging the legal provision that allows abortions based on presumed mental health injury without requiring evaluation by a psychiatrist. Deepak Kumar, the petitioner, has sought a declaration that a key clause under the Medical Termination of Pregnancy (MTP) Act, 1971 — particularly Section 3(2) and Explanation 1 — is unconstitutional. He has contended that the provision violates Articles 14 and 21 of the Constitution by allowing gynaecologists to terminate pregnancies on mental health grounds, even though they are not qualified to assess psychological conditions. He has also asked the court to rule that abortions should only be allowed when the life of the woman or the foetus is in immediate danger, not in cases of failed contraception or presumed mental anguish. The PIL, filed through advocates Dr Pankaj Nanhera, Sanchar Anand, Nitin Verma, and Yogesh Vashista, came up for hearing on Wednesday before the division bench of Chief Justice Sheel Nagu and Justice Sanjiv Berry. The bench issued notice to the Union government and fixed the next hearing for September 16. Section 3(2) of the MTP Act allows a registered medical practitioner to terminate a pregnancy if it risks the woman's life or may cause 'grave injury' to her physical or mental health. For pregnancies up to 20 weeks, the opinion of one doctor is sufficient; between 20 and 24 weeks, two doctors must concur for certain categories of women. Explanation 1 to this section presumes that if a pregnancy results from the failure of contraceptive methods, the resulting mental anguish is automatically considered a grave mental health injury, making abortion legally permissible. The PIL argues that: The petitioner contends that these provisions enable abortions in situations that fall outside the core intent of the MTP Act, and that such broad presumptions may undermine fetal rights and open doors to female foeticide. Among other reliefs, Deepak Kumar has requested the court to: The court has admitted the petition and listed it for further hearing on September 16.
Time of India
29 minutes ago
- Time of India
Eli Lilly's experimental GLP-1 pill may rival Ozempic and Wegovy? Check how much weight you could lose
Eli Lilly's weight loss pill doesn't appear to work as well as Wall Street had hoped. The drugmaker said Thursday the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in a late-stage trial. The result falls on the lower end of Wall Street's expectations. Shares of the company fell around 13% on Thursday, according to CNBC. Meanwhile, shares of rival Novo Nordisk, which is also working to bring an obesity pill to the market, jumped more than 7% on Thursday. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program Eli Lilly, which makes the injectable drugs Zepbound to treat obesity and Mounjaro and Trulicity to treat diabetes, is among several companies chasing an effective pill form of GLP-1s. The only such pill available so far comes with strict diet restrictions and is approved to treat diabetes. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Web Search search Search Now Undo Lilly says that no food or water restrictions are needed with the experimental oral medication, orforglipron, and it can be taken any time of day. ALSO READ: Firefly Aerospace ignites Wall Street as it raises $868 million in biggest space IPO. All about SpaceX rival Live Events Eli Lily on daily GLP-1 pills Eli Lilly announced that its new orforglipron pill led to an average weight loss of up to 27.3 pounds, based on results from the first of two Phase 3 trials involving over 3,100 overweight or obese adults. "With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments," Kenneth Custer, an executive vice president and president of Lilly Cardiometabolic Health, said in a statement. "With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." ALSO READ: VA terminates major union contracts and it will impact over 400,000 federal workers. What's at stake for you? Investors had high hopes that Lilly's pill, orforglipron, would match the effectiveness of Novo Nordisk's blockbuster weight-loss injection, Wegovy. In key trials, Wegovy helped users lose around 14% to 15% of their body weight — slightly below the weight loss seen with Lilly's competing shot, Zepbound. 'There was hope that this would be a wonder drug,' BMO analyst Evan Seigerman said of Lilly's pill. 'What this shows to me is that it's still a good drug, but it's bound by the limitations of being a GLP-1.' Eli Lilly said that all adults participating in its Phase 3 trials experienced weight loss while taking orforglipron. Participants on the highest dose—36 mg—lost an average of 27 pounds over 72 weeks, equating to about 12% of their body weight. While this result is significant, it falls slightly short of the weight loss typically seen with some injectable treatments with the drugmaker noticing that about 10% of participants on the highest dose chose to discontinue the pill. ALSO READ: $1,702 stimulus check in August: Last chance to apply for PDF closes soon. Check key dates, eligibility, tax implication Beyond weight loss, trial participants saw improvements in cardiovascular markers, including reductions in systolic blood pressure, non-HDL cholesterol, and triglycerides. Negative side effects were similar in frequency and nature to those observed with injectable GLP-1 medications. The most commonly reported side effects were mild to moderate gastrointestinal issues such as nausea, constipation, indigestion, diarrhea, and vomiting. Eli Lilly is also evaluating orforglipron's effectiveness in adults with Type 2 diabetes. In April, the company shared that the pill may help lower hemoglobin A1C levels—a key indicator of average blood sugar over two to three months—while also supporting weight loss. Eli Lilly aims to seek global regulatory approval for its daily oral orforglipron pill by the end of 2025, positioning itself alongside rival Novo Nordisk, which is pursuing approval for an oral form of its Wegovy (semaglutide) treatment. However, federal health regulators are expected to require more comprehensive data on the drug's safety, tolerability, and effectiveness before moving forward with any potential approval.
Time of India
an hour ago
- Time of India
Study reveals eating French fries can increase the risk of Type 2 diabetes by a shocking percentage
Image credits: Getty Images If French fries have been your go-to order at restaurants and a favoured side dish with meals, then it might be time to cut them out of your life. According to a new study published in The BMJ on August 6, 2025, the potato-based dish can elevate the risk of Type 2 diabetes by 20%. But, if you swap these out for whole-grain foods, these odds could decrease by 19%, according to the same study. The study focused on data involving more than 205,000 people enrolled in the Nurses' Health Study, the Nurses' Health Study II and the Health Professionals Follow-up Study. The participants filled out detailed dietary questionnaires for a long period for three decades, which included questions about how many times a week they ate French fries, whether they baked, boiled or mashed potatoes and how many times they ate whole grains in a week. Their health was also tracked to gain results, and over the period, a shocking 22,299 participants developed Type 2 diabetes. 'The public health message here is simple and powerful: Small changes in our daily diet can have an important impact on the risk of type 2 diabetes. Limiting potatoes — especially limiting French fries — and choosing healthy, whole grain sources of carbohydrate could help lower the risk of type 2 diabetes across the population,' said Dr Walter Willett, study co-author and professor of epidemiology and nutrition at Harvard University. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Kate Middleton's Daring Outfit Took Prince William's Breath Away Crowdy Fan Undo Who is to blame: French fries or potatoes? Image credits: Getty Images However, is it the fries or the vegetable itself? 'We're shifting the conversation from, 'Are potatoes good or bad?' to a more nuanced — and useful — question: How are they prepared, and what might we eat instead?' said Seyed Mohammad Mousavi, a postdoctoral research fellow in Harvard's Department of Nutrition and lead author of the study. It does matter how the potatoes are cooked. While just three servings a week of French fries elevated the diabetes risk by 20%, eating the vegetable as baked, boiled or mashed had absolutely no influence on the risk of the disease. Whole grains for the rescue Image credits: Getty Images Replacing the French fries order with whole grains, such as whole grain pastas or bread, reduced the risk of the disease by up to 19%. Even substituting whole grains with refined ones can add to the lowered diabetes risk. These findings were substantiated by 2 separate analyses where data from numerous previous studies involving more than 500,000 people led to similar results when it came to the battle of French fries versus whole grains. 'For policymakers, our findings highlight the need to move beyond broad food categories and pay closer attention to how foods are prepared and what they're replacing," Willett said in a Harvard news release. "Not all carbs — or even all potatoes — are created equal, and that distinction is crucial when it comes to shaping effective dietary guidelines.'
